Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKYO vs NBIX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NBIX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

NBIX Overall Winner 6-Pillar Tally: OKYO 0 – 6 NBIX Matrix Metrics: OKYO 1 – 9 NBIX

As of Nov 20, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas NBIX carries 40.0/100 (SELL) at $150.57 (12.2x Forward P/E, 26.6% operating margin).

  • Composite vs. Pillar Nuance: While OKYO currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. NBIX 40.0/100 SELL), NBIX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+41.2% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile NBIX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKYO vs NBIX
OKYO NASDAQ
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38
NBIX NASDAQ Head-to-Head Winner
Neurocrine Biosciences Inc
Biological Products, (No Disgnostic Substances)
$150.57
-3.84% 1D
Market Cap $15.8B
TTM Revenue $3.70B
Forward P/E 12.2x
Beta / 30D Vol 0.67β · 56% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.1 · SMA20: $159.05 · SMA50: $149.03

6-Pillar Scorecard Institutional Category Breakdown (OKYO 0 – 6 NBIX)

Columns: Metric · OKYO · NBIX
1. Valuation Multiples NBIX
Forward P/E N/M 12.2x
Trailing P/E N/M 24.2x
PEG Ratio N/M 0.32x
EV / Revenue N/M 4.2x
2. Growth & Scale NBIX
Revenue Growth (YoY) +0.0% +41.2%
Earnings Growth (YoY) +0.0% -3.9%
TTM Revenue (USD) N/A $3.70B
Market Cap $62.7M $15.8B
3. Profitability & Quality NBIX
Gross Margin N/A 64.7%
Operating Margin 0.0% 26.6%
Net Profit Margin 0.0% 19.0%
Return on Equity (ROE) -263.8% 20.4%
4. Balance Sheet & Cash Flow NBIX
Cash Generation (TTM) N/A $1.04B
Cash Flow Margin N/A 28.1%
Net Cash / Leverage $0.23 Book/Sh · -263.8% ROE $249M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NBIX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 33.9% (26th %ile)
Put/Call OI Skew N/A 0.85x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat NBIX
OpEx & R&D Intensity N/A 38.1% of Rev ($1.41B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKYO (1) vs NBIX (9)
Institutional Metric OKYO NBIX Criterion Row Edge
Market Capitalization
Scale
$62.7M $15.8B Larger Scale NBIX
Trailing P/E Ratio
Valuation
N/M 24.2x Lower Multiple NBIX
Forward P/E Ratio
Valuation
N/M 12.2x Lower Multiple NBIX
Revenue Growth (YoY)
Growth
+0.0% +41.2% Higher Growth NBIX
Operating Margin (TTM)
Profitability
0.0% 26.6% Higher Margin NBIX
Net Profit Margin
Profitability
0.0% 19.0% Higher Margin NBIX
Return on Equity (ROE)
Capital Efficiency
-263.8% 20.4% Higher ROE NBIX
52-Week Range Position
Momentum
3% ($1–$3) 44% ($122–$186) Stronger Trend NBIX
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 0.67β · 56% Vol Lower Realized Risk NBIX
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 40.0 / 100 (SELL) Higher Composite OKYO
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.70B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 64.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.32x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.23 Book/Sh · -263.8% ROE) $1.04B ($249M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NBIX +32.29 pp
OKYO: -27.21% · NBIX: +5.08%
3M Horizon NBIX +27.06 pp
OKYO: -28.67% · NBIX: -1.61%
6M Horizon NBIX +30.45 pp
OKYO: -34.36% · NBIX: -3.91%
1Y Horizon NBIX +56.09 pp
OKYO: -47.03% · NBIX: +9.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs NBIX. Trailing 12-month operating profitability (OKYO 0.0% vs NBIX 26.6%) and valuation multiples (OKYO N/M vs NBIX 12.2x Forward P/E) are benchmarked directly in Pillar 4 below.

OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M
NBIX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.70B
Gross Margin64.7%
Op. Margin26.6%
ROE / Fwd P/E20.4% · 12.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NBIX CONSOLIDATION
95d in phase · OBV DISTRIBUTION
Current IV 33.9%
IV Percentile 26th %ile
Put/Call OI Skew 0.85x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NBIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $165.31 · IV 31.1%

NBIX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($16,531)

Compare $16,531 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 31.1% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $170 / $180 Bull Call Spread

Buy 1x $170C · Sell 1x $180C · 32d

Net Entry $115 Debit
T+5d @ +5% Move +$159 (+138%)
Max Risk / Buffer $115 Capped
5d Edge & Liquidity 1.7x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $160 / $150 Bull Put Spread

Sell 1x $160P · Buy 1x $150P · 32d

Net Entry $273 Credit
Max Credit / Yield +$273 (+37.6% RoM)
Max Risk / Buffer -4.9% Cushion ($727 Mgn)
5d Edge & Liquidity 65% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $155P / $170-$180C Seagull

Sell 1x $155P · Buy 1x $170/$180C · 32d

Net Entry $115 Credit
T+5d @ +5% Move +$328 (+13.7% RoM)
Max Risk / Buffer -6.2% Put Cushion ($2,390 Mgn)
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NBIX Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $15.8B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment 38.1% of Rev ($1.41B)
90D Engineering Disclosures 0 Published

Investor FAQ OKYO vs NBIX Key Questions & Quantitative Answers

As of Nov 20, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over OKYO Pharma Limited (OKYO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKYO carries a Unified Composite Score of 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin), whereas NBIX carries 40.0/100 (SELL) at $150.57 (12.2x Forward P/E, 26.6% operating margin). Composite vs. Pillar Nuance: While OKYO currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. NBIX 40.0/100 SELL), NBIX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+41.2% vs. +0.0% YoY). Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile NBIX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NBIX leads the Growth & Scale pillar: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NBIX at +41.2% YoY revenue growth and -3.9% YoY earnings growth on $3.70B TTM revenue (64.7% gross margin, 26.6% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $3.70B for NBIX. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($1.41B) (0 disclosures) for NBIX.

NBIX screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NBIX trades at 12.2x Forward P/E, 24.2x Trailing P/E, 0.32x PEG, and 4.2x EV/Revenue (28.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus NBIX (20.4% ROE) capital efficiency.

In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, NBIX carries 33.9% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.85x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.